Clinical trial
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who…
NCT00253526 · National Cancer Institute (NCI), NIH · Withdrawn
Key facts
| NCT number | NCT00253526 |
|---|---|
| Title | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer |
| Official title | Phase II Randomized Study of Surgical Resection and Adjuvant Gemcitabine Hydrochloride With Versus Without Bevacizumab in Patients With Adenocarcinoma of the Pancreas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage I Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer |
| Intervention type | Drug, Procedure |
| Interventions | bevacizumab, gemcitabine hydrochloride, adjuvant therapy, anti-cytokine therapy, antiangiogenesis therapy, antibody therapy, biological therapy, chemotherapy, conventional surgery, growth factor antagonist therapy and 2 more |
| Enrollment | 0 |
| First posted | Nov 15, 2005 |
| Last update posted | Apr 28, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: